Key Insights

Highlights

Treatment Research

1 treatments under study, led by Pegzilarginase

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06582524Phase 3Completed

Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency

Showing all 1 trials

Research Network

Common Treatments

  • Pegzilarginase1

Active Sponsors

  • Immedica Pharma AB1

Top Investigators

Related Conditions

  • Arginase 1 Deficiency1

Activity Timeline